BRAF and melanoma: Notably, the combination of nivolumab and ipilimumab has demonstrated numerically superior progression-free survival (PFS) and overall survival (OS) compared to nivolumab alone (although this was an exploratory comparison), with particular benefit in patients with BRAF-mutant melanoma.8